Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 4, 2001, Pages 230-238

  Porter, David L ^a   Luger, Selina M ^a   Duffy, Kathleen M ^a   Stadtmauer, Edward A ^a   Laport, Ginna ^a   Schuster, Stephen J ^a   Orloff, Gregory ^b   Tsai, Donald ^a   McDaid, Kevin ^a   Kathakali, Addya ^c   Leonard, Debra G B ^c   Antin, Joseph H ^d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b Inova Fairfax Bone Marrow T   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Allogeneic cell therapy; Graft versus tumor activity; Stem cell transplantation

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE DISEASE; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGRAFT; ARTICLE; AUTOTRANSPLANTATION; BLOOD CELL; BONE MARROW APLASIA; CANCER RECURRENCE; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOCYTE; MYELOMA; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL; RISK ASSESSMENT; STEM CELL TRANSPLANTATION;

EID: 0035041461     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11349810     Document Type: Article

References (38)

1. Blau I, Basara N, Bischoff M, et al. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant. 2000; 25:41-45.
2. Ringden O, Labopin M, Gorin N, et al. The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Bone Marrow Transplant. 2000;25:1053-1058.
3. Radich J, Gooley T, Snaders J, Anasetti C, Chauncey T, Appelbaum F. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant. 2000;6:272-279.
4. Horowitz M, Gale R, Sondel P, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
5. Collins R, Shpilberg O, Drobyski W, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
6. Kolb H, Schattenberg A, Goldman J, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
7. Porter D, Roth M, McGarigle C, Ferrara J, Antin J. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100-106.
8. Drobyski W, Keever C, Roth M, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310-2318.
9. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87:2195-2204.
10. Porter D, Connors J, VanDeerlin V, et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol. 1999;17:1234-1243.
11. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
12. Khouri I, Keating M, Korbling M, et al. Transplant-lite: induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
13. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
14. Spitzer T, McAfee S, Sackstein R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant. 2000;6:309-320.
15. McSweeney P, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant. 1999;5:192-203.
16. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234-3241.
17. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant. 2000;26: 251-255.
18. Anderlini P, Giralt S, Andersson B, et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000;26:615-620.
19. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15: 825-828.
20. Vose J, Bierman P, Anderson J, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood. 1992;80:2142-2148.
21. Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant. 1998;21:887-892.
22. Chiang K, Weisdorf D, Davies S, et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant disease. Bone Marrow Transplant. 1996;17:39-42.
23. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant. 1997;20:859-862.
24. Carella A, Champlin R, Slavin S, McSweeny P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant. 2000;25:345-350.
25. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant. 2000;25:1021-1028.
26. Flowers M, Leisenring W, Beach K, et al. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. Biol Blood Marrow Transplant. 2000;6:321-326.
27. Anderson J, Litzow M, Appelbaum F, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21 year Seattle experience. J Clin Oncol. 1993;11:2342-2350.
28. Jones R, Ambinder R, Piantadosi S, Santos G. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649-653.
29. Wasch R, Reisser S, Hahn J, et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant. 2000;26:243-250.
30. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New Engl J Med. 2000;343: 750-758.
31. Yu C, Seidel K, Nash R, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-vs-host disease among lethally irradiated dogs given DLA-non-identical unrelated marrow grafts. Blood. 1998;91:2581-2587.
32. Mackinnon S, Papadopoulos E, Carabasi M, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
33. Grigg A, Bardy P, Byron K, Seymour J, Szer J. Fludarabine-based nonmyeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant. 1999;23:107-110.
34. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419-2425.
35. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86: 4337-4343.
36. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91:3671-3680.
37. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719-1724.
38. Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol. 2000;18:3918-3924.